Tecovirimat treatment of clade II mpox: a virological analysis of a randomised, double-blind, phase 3 trial

By afschroeder • July 30, 2026

Vyshenska D, Reed JC, Roychoudhury P, Zheng L, Olefsky M, Ritz J, McCarthy C, Saha PT, Hao L, Mills MG, Shea A, Nunley BE, Javan AC, Brooks KM, Nachman S, Eron J, Gandhi RT, Currier J, Fischer WA 2nd, Zucker J, Wilkin T, Greninger AL; ACTG A5418–STOMP protocol team. Tecovirimat treatment of clade II mpox: a virological analysis of a randomised, double-blind, phase 3 trial. Lancet Microbe. 2026 Jul 29:101464. doi: 10.1016/j.lanmic.2026.101464. Epub ahead of print. PMID: 42526486.

Tags: Infectious Diseases, Publications

Advancing the inclusion of pregnant and lactating populations in HIV PrEP research: ethical, regulatory, and surveillance recommendations from a multisectoral working group

Osakwe CE, Schaefer R, Donaldson L, Abiodun AS, Chatani-Gada M, Chigome AK, Day S, Deaton C, Elemuwa UG, Ingold H, Joseph Davey D, Kersey K,[...]

A Community-Based Intervention to Increase PrEP Initiation and Reduce Internalized Stigma: A Randomized Trial Among Black Sexual Minority Men in Prince George’s County, Maryland

Turpin RE, Wilson GT, Davidson Mhonde RR, Camp AD, Dyer TV, Mayer KH, Liu H, Coates T, Boekeloo B. A Community-Based Intervention to Increase PrEP[...]

Altered bile acid metabolism in people with HIV correlates with systemic and intestinal inflammation

Irwin S, Elliott J, Li F, Ruiz P, Anton PA, Du X, Fulcher JA. Altered bile acid metabolism in people with HIV correlates with systemic[...]